Publications Lene Uhrbom

Publications in DiVA

Publications in PubMed

Selected publications:

  1. Maturi NP, Tan E-J, Xie Y, Sundström A, Bergström T, Jiang Y, Uhrbom L. A molecularly distinct subset of glioblastoma requires serum-containing media to establish sustainable bona fide glioblastoma stem cell cultures. Glia 2019. PMID: 31868967, DOI: 10.1002/GLIA.23773
  2. Xie Y, Sundström A, Maturi NP, Tan EJ, Marinescu VD, Jarvius M, Tirfing M, Jin C, Chen L, Essand M, Swartling FJ, Nelander S, Jiang Y, Uhrbom L. LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients. J Pathology 2019. PMID: 30357839, DOI: 10.1002/path.5186
  3. Jiang Y, Marinescu VD, Xie Y, Jarvius M, Haglund C, Maturi, NP, Olofsson S, Lindberg N, Olofsson T, Leijonmarck C, Hesselager G, Alafuzoff I, Fryknäs M, Larsson R, Nelander S, and Uhrbom L. Glioblastoma cell malignancy and drug sensititvity are affected by the cell of origin. Cell Reports 2017. PMID: 28467901, DOI: 10.1016/j.celrep.2017.04.053
  4. Sreedharan S, Maturi NP, Xie Y, Sundström A, Jarvius M, Libard S, Alafuzoff I, Weishaupt H, Fryknäs M, Larsson R, Swartling FJ and Uhrbom L. Mouse models of pediatric supratentorial high-grade glioma reveal how cell of origin influences tumor development and phenotype. Cancer Research 2017. PMID: 28115362, DOI: 10.1158/0008-5472.CAN-16-2482
  5. Xie Y, Bergström T, Jiang Y, Johansson P, Marinescu VD, Lindberg N, Segerman A, Wicher G, Niklasson M, Baskaran S, Sreedharan S, Everlien I, Kastemar M, Hermansson A, Elfineh L, Libard S, Holland EC, Hesselager G, Alafuzoff I, Westermark B, Nelander S, Forsberg-Nilsson K, and Uhrbom L. The human glioblastoma cell culture resource: validated cell models representing all molecular subtypes. EbioMedicine 2015. PMID: 26629530, PMCID: PMC4634360, DOI: 10.1016/j.ebiom.2015.08.026
  6. Lindberg N, Jiang Y, Xie Y, Bolouri H, Kastemar M, Olofsson T, Holland EC, and Uhrbom L. Oncogenic signaling is dominant to cell of origin and dictates astrocytic or oligodendroglial tumor development from oligodendrocyte precursor cells. J Neuroscience 2014, PMID: 25355217, PMCID: PMC6608431, DOI: 10.1523/JNEUROSCI.2977-14.2014
  7. Westermark UK, Lindberg N, Roswall P, Bråsäter D, Helgadottir HR, Hede S-M, Zetterberg A, Jasin M, Nistér M, and Uhrbom L. RAD51 can inhibit PDGF-B induced gliomagenesis and genomic instability. Neuro-Oncology 2011. PMID: 21926087, PMCID: PMC3223091, DOI: 10.1093/neuonc/nor131
  8. Jiang Y, Boije M, Westermark B, and Uhrbom L. PDGF-B can sustain self-renewal and tumorigenicity of experimental glioma-derived cancer-initiating cells by preventing oligodendrocyte differentiation. Neoplasia 2011. PMID: 21677873, PMCID: PMC3114243, DOI: 10.1593/neo.11314
  9. Lindberg N, Kastemar M, Olofsson T, Smits A, and Uhrbom L. Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma. Oncogene 2009. PMID: 19421151, DOI: 10.1038/onc.2009.76
  10. Uhrbom L, Nerio E, and Holland EC. Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nature Medicine 2004. PMID: 15502845, DOI: 10.1038/nm1120